Oasmia Pharmaceutical spins out veterinary oncology assets

Oasmia Pharmaceutical spins out veterinary oncology assets
Credit: Shutterstock.com/ SMA Studio

Oasmia Pharmaceutical, a developer of a new generation of drugs within human and veterinary oncology, has spun out its veterinary oncology assets to its wholly owned, US-based subsidiary, AdvaVet.

AdvaVet can now begin to unlock value for Oasmia shareholders through the development and commercialisation of two new chemotherapy drugs that specifically target companion animals.

AdvaVet has started to build infrastructure in the US and has recently hired an experienced CEO and CFO from the veterinary industry, as well as a predominately US-based Board of Directors.

The company will gradually build out its commercial infrastructure in parallel with completing the clinical development of Doxophos Vet and Paccal Vet.